Combination immune checkpoint blockade as an effective therapy for mesothelioma

Vanessa Fear, Caitlin Michelle Tilsed, Hui En J Chee, Catherine Forbes, Thomas Casey, Jessica Solin, Sally Lansley, Willem Lesterhuis, Ian Dick, Anna Nowak, Bruce Robinson, Richard Lake, Scott Fisher

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Mesothelioma is an aggressive asbestos induced cancer with extremely poor prognosis and limited treatment options. Immune checkpoint blockade (ICPB) has demonstrated effective therapy in melanoma and is now being applied to other cancers, including mesothelioma. However, the efficacy of ICPB and which immune checkpoint combinations constitute the best therapeutic option for mesothelioma have yet to be fully elucidated. Here, we used our well characterised mesothelioma tumour model to investigate the efficacy of different ICBP treatments to generate effective therapy for mesothelioma. We show that tumour resident regulatory T cell co-express high levels of CTLA-4, OX40 and GITR relative to T effector subsets and that these receptors are co-expressed on a large proportion of cells. Targeting any of CTLA-4, OX40 or GITR individually generated effective responses against mesothelioma. Furthermore, the combination of αCTLA-4 and αOX40 was synergistic, with an increase in complete tumour regressions from 20% to 80%. Other combinations did not synergise to enhance treatment outcomes. Finally, an early pattern in T cell response was predictive of response, with activation status and ICP receptor expression profile of T effector cells harvested from tumour and dLN correlating with response to immunotherapy. Taken together, these data demonstrate that combination ICPB can work synergistically to induce strong, durable immunity against mesothelioma in an animal model.
Original languageEnglish
Article numbere1494111
Number of pages14
JournalOncolmmunology
DOIs
Publication statusE-pub ahead of print - 30 Jul 2018

Fingerprint

Mesothelioma
Neoplasms
Therapeutics
Asbestos
Regulatory T-Lymphocytes
Immunotherapy
Immunity
Melanoma
Animal Models
T-Lymphocytes

Cite this

@article{5abb2fe3b144444db25208dd26c2feeb,
title = "Combination immune checkpoint blockade as an effective therapy for mesothelioma",
abstract = "Mesothelioma is an aggressive asbestos induced cancer with extremely poor prognosis and limited treatment options. Immune checkpoint blockade (ICPB) has demonstrated effective therapy in melanoma and is now being applied to other cancers, including mesothelioma. However, the efficacy of ICPB and which immune checkpoint combinations constitute the best therapeutic option for mesothelioma have yet to be fully elucidated. Here, we used our well characterised mesothelioma tumour model to investigate the efficacy of different ICBP treatments to generate effective therapy for mesothelioma. We show that tumour resident regulatory T cell co-express high levels of CTLA-4, OX40 and GITR relative to T effector subsets and that these receptors are co-expressed on a large proportion of cells. Targeting any of CTLA-4, OX40 or GITR individually generated effective responses against mesothelioma. Furthermore, the combination of αCTLA-4 and αOX40 was synergistic, with an increase in complete tumour regressions from 20{\%} to 80{\%}. Other combinations did not synergise to enhance treatment outcomes. Finally, an early pattern in T cell response was predictive of response, with activation status and ICP receptor expression profile of T effector cells harvested from tumour and dLN correlating with response to immunotherapy. Taken together, these data demonstrate that combination ICPB can work synergistically to induce strong, durable immunity against mesothelioma in an animal model.",
author = "Vanessa Fear and Tilsed, {Caitlin Michelle} and Chee, {Hui En J} and Catherine Forbes and Thomas Casey and Jessica Solin and Sally Lansley and Willem Lesterhuis and Ian Dick and Anna Nowak and Bruce Robinson and Richard Lake and Scott Fisher",
year = "2018",
month = "7",
day = "30",
doi = "10.1080/2162402X.2018.1494111",
language = "English",
journal = "Oncolmmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - Combination immune checkpoint blockade as an effective therapy for mesothelioma

AU - Fear, Vanessa

AU - Tilsed, Caitlin Michelle

AU - Chee, Hui En J

AU - Forbes, Catherine

AU - Casey, Thomas

AU - Solin, Jessica

AU - Lansley, Sally

AU - Lesterhuis, Willem

AU - Dick, Ian

AU - Nowak, Anna

AU - Robinson, Bruce

AU - Lake, Richard

AU - Fisher, Scott

PY - 2018/7/30

Y1 - 2018/7/30

N2 - Mesothelioma is an aggressive asbestos induced cancer with extremely poor prognosis and limited treatment options. Immune checkpoint blockade (ICPB) has demonstrated effective therapy in melanoma and is now being applied to other cancers, including mesothelioma. However, the efficacy of ICPB and which immune checkpoint combinations constitute the best therapeutic option for mesothelioma have yet to be fully elucidated. Here, we used our well characterised mesothelioma tumour model to investigate the efficacy of different ICBP treatments to generate effective therapy for mesothelioma. We show that tumour resident regulatory T cell co-express high levels of CTLA-4, OX40 and GITR relative to T effector subsets and that these receptors are co-expressed on a large proportion of cells. Targeting any of CTLA-4, OX40 or GITR individually generated effective responses against mesothelioma. Furthermore, the combination of αCTLA-4 and αOX40 was synergistic, with an increase in complete tumour regressions from 20% to 80%. Other combinations did not synergise to enhance treatment outcomes. Finally, an early pattern in T cell response was predictive of response, with activation status and ICP receptor expression profile of T effector cells harvested from tumour and dLN correlating with response to immunotherapy. Taken together, these data demonstrate that combination ICPB can work synergistically to induce strong, durable immunity against mesothelioma in an animal model.

AB - Mesothelioma is an aggressive asbestos induced cancer with extremely poor prognosis and limited treatment options. Immune checkpoint blockade (ICPB) has demonstrated effective therapy in melanoma and is now being applied to other cancers, including mesothelioma. However, the efficacy of ICPB and which immune checkpoint combinations constitute the best therapeutic option for mesothelioma have yet to be fully elucidated. Here, we used our well characterised mesothelioma tumour model to investigate the efficacy of different ICBP treatments to generate effective therapy for mesothelioma. We show that tumour resident regulatory T cell co-express high levels of CTLA-4, OX40 and GITR relative to T effector subsets and that these receptors are co-expressed on a large proportion of cells. Targeting any of CTLA-4, OX40 or GITR individually generated effective responses against mesothelioma. Furthermore, the combination of αCTLA-4 and αOX40 was synergistic, with an increase in complete tumour regressions from 20% to 80%. Other combinations did not synergise to enhance treatment outcomes. Finally, an early pattern in T cell response was predictive of response, with activation status and ICP receptor expression profile of T effector cells harvested from tumour and dLN correlating with response to immunotherapy. Taken together, these data demonstrate that combination ICPB can work synergistically to induce strong, durable immunity against mesothelioma in an animal model.

U2 - 10.1080/2162402X.2018.1494111

DO - 10.1080/2162402X.2018.1494111

M3 - Article

JO - Oncolmmunology

JF - Oncolmmunology

SN - 2162-4011

M1 - e1494111

ER -